SCHEMBL3274276

SCHEMBL3274276

CS(=O)(=O)Nc1ccc(Cl)cc1NC(=O)C=Cc1ccc2ccccc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.51
MAPT P10636 3/20 0.49
TP53 P04637 2/20 0.49
HCAR2 Q8TDS4 1/20 0.45
POLB P06746 1/20 0.45
TRPA1 O75762 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
MMP1 P03956 1/20 0.44
MMP2 P08253 1/20 0.44
MMP9 P14780 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3274273 1.00 EGFR (0.51) EGFRMAPTTP53HCAR2POLB
SCHEMBL3278122 0.87 EGFR (0.52) EGFRMAPTTP53HCAR2TRPA1
SCHEMBL3278130 0.87 EGFR (0.52) EGFRMAPTTP53HCAR2TRPA1
SCHEMBL3274102 0.86 EGFR (0.48) EGFRMAPTTP53HCAR2POLB
SCHEMBL3274110 0.86 EGFR (0.48) EGFRMAPTTP53HCAR2POLB
SCHEMBL3273770 0.85 EGFR (0.54) EGFRMAPTTP53HCAR2POLB
SCHEMBL3273766 0.85 EGFR (0.54) EGFRMAPTTP53HCAR2POLB
SCHEMBL3273565 0.84 EGFR (0.46) EGFRMAPTTP53HCAR2POLB
SCHEMBL3273574 0.84 EGFR (0.46) EGFRMAPTTP53HCAR2POLB
SCHEMBL3280717 0.82 EGFR (0.50) EGFRMAPTTP53HCAR2TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US claimed
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-08 US disclosed
EP-2121569-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2009-11-25 EP disclosed
WO-2008074755-A2 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087496-A1 NOVEL CINNAMIC AMIDE DERIVATIVES USEFUL AS ION CHANNEL MODULATORS TRPV1, TRPA1, TRPM8 EGFR 2980/4885MAPT 1755/4885TP53 4670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.